$COCP

FROST PHILLIP MD ET AL purchased $10K of COCP (indirect holdings)

FROST PHILLIP MD ET AL purchased 10,000 indirectly-held shares of Cocrystal Pharma, Inc. (COCP) at $0.98 on 2026-08-05.

Original reporting
SEC EDGAR · FROST PHILLIP MD ET AL
Published Aug 6, 2026, 9:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 9:46 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$COCP
Neutral
low confidence
Mentioned
$COCP
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$COCPNeutralLow
01

Why it matters

The newest fact is the specific open-market purchase size, price, and date by a director/10% owner via indirect holdings, without any accompanying company news.

02

Market read

Traders may note the insider buy as a minor sentiment input, but there is no fundamental update in the text.

03

What to watch

No 10b5-1 plan is stated, but the filing does not disclose intent, timing constraints, or whether the buyer’s broader position is changing materially beyond the post-transaction share count.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-06, transaction dated 2026-08-05

Background

This is an SEC Form 4 insider transaction disclosure for Cocrystal Pharma, Inc.

Company-level read

Ticker impact

$COCPNeutralLow confidence
Context

Cocrystal Pharma disclosed a Form 4 showing a director and 10% owner bought 10,000 shares at $0.9816 on 2026-08-05 via indirect holdings.

Expected impact

Low near-term impact; any effect is likely sentiment-driven and limited to microcap liquidity.

Evidence & confidence

Form 4 insider buys can be read as confidence signals, but the disclosed value ($9,816) is modest and the article provides no accompanying operational or financial catalyst.

Market effects

No sector read-through is provided beyond a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

The purchase is indirect and small, so it may reflect routine liquidity management or non-informational factors rather than a bullish thesis.

Key entities

  • Cocrystal Pharma, Inc.

    Subject of the Form 4 insider transaction disclosure (COCP).

  • Frost Phillip MD et al

    Director and 10% owner reporting an indirect open-market purchase of 10,000 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$DELLLow

Silver Lake Partners V DE (AIV), L.P. (Durban Egon) sold $14.9M of DELL (indirect holdings)

Silver Lake Partners V DE (AIV), L.P. sold 26,990 indirectly-held shares of Dell Technologies Inc. (DELL) at an average of $552.79 ($542.78–$564.46, $14.92M total) across 22 trades on 2026-09-15. Filed jointly with Silver Lake Technology Associates V, L.P. (Director), SLTA V (GP), L.L.C. (Director), Silver Lake Group, L.L.C. (Director) and Durban Egon (Director).

$DELLLow

Silver Lake Partners IV, L.P. (Durban Egon) sold $28.0M of DELL (indirect holdings)

Silver Lake Partners IV, L.P. sold 50,728 indirectly-held shares of Dell Technologies Inc. (DELL) at an average of $552.61 ($542.78–$563.66, $28.03M total) across 21 trades on 2026-09-15. Filed jointly with Silver Lake Technology Associates IV, L.P. (Director), SLTA IV (GP), L.L.C. (Director), Silver Lake Group, L.L.C. (Director) and Durban Egon (Director).